Dr Saad Usmani speaks to ecancer at the 2019 ASH meeting in Orlando about results from the CANDOR study.
The phase III study compared carfilzomib, dexamethasone, and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM), with a primary endpoint of progression-free survival (PFS).
Dr Usmani reports that the addition of daratumumab benefitted PFS and achieved deeper responses, but also had more grade 3 or higher adverse events.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.